Horizon Space Acquisition I agrees to merge with ArcheNova Biotech in deal targeting Nasdaq listing

Horizon Space Acquisition I Corp. entered a definitive business combination agreement with clinical-stage biopharma ArcheNova Biotech. The deal would create a new Cayman Islands parent, ArcheNova Technology, expected to list on Nasdaq upon closing. Transactions include mergers that leave HSPO and ArcheNova as wholly owned subsidiaries of the new parent. Consideration will be paid in parent ordinary shares to HSPO and ArcheNova shareholders; HSPO warrants will convert into parent warrants. Closing is targeted for the first quarter of 2027, subject to shareholder and regulatory approvals and other customary conditions. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Horizon Space Acquisition I Corp. published the original content used to generate this news brief via (Ref. ID: 202610130700ACCESSWRNAPR_____1235647) on October 13, 2026, and is solely responsible for the information contained therein. (C)